Aniket Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-12-2024
- Paid Up Capital ₹ 4.00 M
as on 16-12-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 1.75 Cr
as on 16-12-2024
- Revenue 17872.03%
(FY 2022)
- Profit -28842.82%
(FY 2022)
- Ebitda -21044.99%
(FY 2022)
- Net Worth -57.89%
(FY 2022)
- Total Assets -58.00%
(FY 2022)
About Aniket Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company has closed loans amounting to ₹1.75 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Patel Sankabhai, Vinaykumar Patel, Narsinhbhai Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24111GJ2006PTC048288
- Company No.
048288
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2006
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aniket Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Patel Sankabhai  | Director | 19-May-2006 | Current |
| Vinaykumar Patel | Director | 19-May-2006 | Current |
| Narsinhbhai Patel | Director | 19-May-2006 | Current |
| Parimal Patel | Director | 02-Feb-2009 | Current |
Financial Performance of Aniket Pharma.
Aniket Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17872.03% increase. The company also saw a substantial fall in profitability, with a 28842.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 57.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aniket Pharma?
In 2020, Aniket Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ouranos Technologies Private LimitedActive 10 years 7 monthsVinaykumar Patel and Narsinhbhai Patel are mutual person
Charges (Loans)
₹0
₹17.50 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 1.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Nov 2007 | Bank Of Baroda | ₹1.75 Cr | Satisfied |
How Many Employees Work at Aniket Pharma?
Unlock and access historical data on people associated with Aniket Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aniket Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aniket Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
